Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1997-2-7
|
pubmed:abstractText |
Propranolol, a first-generation nonselective beta-adrenoceptor blocking agent, is commonly used to treat pediatric arrhythmias. Atenolol, relatively long-acting, cardioselective beta-adrenoceptor blocking agent, has been successfully used in adults with supraventricular tachycardia (SVT). There is only one report on the use of atenolol in children with SVT; and our report is on the first long-term prospective study to evaluate the use of atenolol in children. A group of 22 children < 18 years of age with clinical SVT were enrolled in the study. The tachycardia was documented on electrocardiograms in each case and was confirmed by electrophysiologic studies in some. Once-a-day oral atenolol was started as a monotherapy. Of the 22 children with various types of SVT, 13 (59%) were well controlled on long-term oral atenolol therapy. The effective dose of atenolol ranged between 0.3 and 1.3 mg/kg/day (median effective dose 0.7 mg/kg/day). Five children had some adverse effects. However, none in the successful group of 13 patients required drug discontinuation because of such effects. Once-a-day oral atenolol as a monotherapy is effective and relatively safe for long-term management of SVT during childhood. It is an attractive alternative beta-adrenoceptor blocking agent for the management of pediatric arrhythmias.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0172-0643
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
231-6
|
pubmed:dateRevised |
2008-2-20
|
pubmed:meshHeading |
pubmed-meshheading:8662045-Adolescent,
pubmed-meshheading:8662045-Adrenergic beta-Antagonists,
pubmed-meshheading:8662045-Atenolol,
pubmed-meshheading:8662045-Child,
pubmed-meshheading:8662045-Female,
pubmed-meshheading:8662045-Humans,
pubmed-meshheading:8662045-Male,
pubmed-meshheading:8662045-Prospective Studies,
pubmed-meshheading:8662045-Tachycardia, Supraventricular,
pubmed-meshheading:8662045-Treatment Outcome
|
pubmed:articleTitle |
Long-term efficacy and safety of atenolol for supraventricular tachycardia in children.
|
pubmed:affiliation |
Department of Pediatrics, James H. Quillen College of Medicine, East Tennessee State University, Johnson City 37604, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|